Opioid Use Disorder and Drugs Used in Pharmacological Treatment

Yıl 2024, Cilt: 33 Sayı: 4, 287 - 293, 31.12.2024

Peyman Ertuğ , Serkan Ecemiş

https://doi.org/10.17827/aktd.1492043

Öz

Opioid use disorder remains a significant source of morbidity and mortality worldwide. Pharmacotherapy plays an important role in the treatment of opioid use disorder to alleviate opioid withdrawal symptoms, reduce relapse and ensure long-term recovery. Treatments with methadone, buprenorphine, naloxone, naltrexone, clonidine have been shown to be effective in correcting opioid use disorder, treating addiction and reducing deaths from overdose. This review provides information on the biological mechanisms of opioid dependence, pharmacokinetics, pharmacodynamics, indications and side effects of pharmacologic agents used in the treatment of opioid use disorder.

Opioid Kullanım Bozukluğu ve Farmakolojik Tedavisinde Kullanılan İlaçlar

Öz

Opioid kullanım bozukluğu dünyada önemli bir şekilde morbidite ve mortalite kaynağı olmaya devam etmektedir. Farmakoterapi, opioid yoksunluk semptomlarını hafifletmek, nüksetmeyi azaltmak ve uzun vadeli iyileşmeyi sağlamak amacıyla opioid kullanım bozukluğunun tedavisinde önemli rol oynamaktadır. Metadon, buprenorfin, nalokson, naltrekson, klonidin ile yapılan tedavilerin, opioid kullanım bozukluğunu düzeltmede, bağımlılığın tedavisinde ve aşırı dozdan ölümleri azaltmada etkili olduğu gösterilmiştir. Bu derlemede, opioid bağımlılığının biyolojik mekanizmaları, opioid kullanım bozukluğunun tedavisinde kullanılan farmakolojik ajanların farmakokinetiği, farmakodinamiği, endikasyonları ve yan etkileri hakkında bilgi verilmektedir.

Anahtar Kelimeler

opioidler, opioid kullanım bozukluğu, farmakoterapiler, nalokson, buprenorfin, naltrekson, metadon, klonidin

Kaynakça

• 1.Wang S. Historical Review: Opiate Addiction and Opioid Receptors. Cell Transplant. 2019 Mar;28(3):233-238. Epub 2018 13.
• 2.Leyrer-Jackson JM, Acuña AM, Olive MF. Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update. Expert Opin Pharmacother. 2022 ;23(16):1819-1830.
• 3.Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020 20;395(10241):1938-1948.
• 4. Scherbaum, N., Bonnet, U. Neurobiology of opioid addiction. Anaesthesist 68 , 179–190 (2019)
• 5.Cao JL, Vialou VF, Lobo MK, Robison AJ, Neve RL, Cooper DC, Nestler EJ, Han MH. Essential role of the cAMP-cAMP response-element binding protein pathway in opiate-induced homeostatic adaptations of locus coeruleus neurons. Proc Natl Acad Sci U S A. 2010 p 28;107(39):17011-6.
• 6.Brown KG, Capili B. CE: Opioid Use Disorder: Pathophysiology, Assessment, and Effective Interventions. Am J Nurs. 2020;120(6):38-46.
• 7.Milivojevic V, Sinha R. Central and Peripheral Biomarkers of Stress Response for Addiction Risk and Relapse Vulnerability. Trends Mol Med. 2018 ;24(2):173-186.
• 8.Nadeau SE, Wu JK, Lawhern RA. Opioids and Chronic Pain: An Analytic Review of the Clinical Evidence. Front Pain Res (Lausanne). 2021 17;2:721357.
• 9.Austin AE, Short NA. Sexual Violence, Mental Health, and Prescription Opioid Use and Misuse. Am J Prev Med. 2020 ;59(6):818-827.
• 10.Thomas AT, Fields KG, Kaye AD, Urman RD. Factors Associated With Prescription Opioid Abuse and Dependence Among Those Reporting Prescription Opioid Misuse: A Retrospective Cross-Sectional Study. Pain Physician. 2022 ;25(4):E669-E679.
• 11.Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017 17;66(10):265-269.
• 12.Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):557-64.
• 13.Webster, Lynn R. MD. Risk Factors for Opioid-Use Disorder and Overdose. Anesthesia & Analgesia 125(5):p 1741-1748, 2017. |
• 14. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012 ;15(3 Suppl):ES67-92.
• 15.Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55-62.
• 16.Douaihy AB, Kelly TM, Sullivan C. Medications for substance use disorders. Soc Work Public Health. 2013;28(3-4):264-78
• 17.Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc. 2012;104(7-8):342-50.
• 18.Bell J, Strang J. Medication Treatment of Opioid Use Disorder. Biol Psychiatry. 2020 ;87(1):82-88.
• 19.Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care BMJ 2021; 373 :n784
• 20.Edinoff, A. N., Fahmy, O. H., Spillers, N. J. et al. Low-Dose Initiation of Buprenorphine: A Narrative Review. Curr Pain Headache Rep 27, 175–181 (2023).
• 21. Whelan PJ, Remski K. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45-50.
• 22.Wang SC, Chen YC, Lee CH, Cheng CM. Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review. Int J Mol Sci. 2019 2;20(17):4294.
• 23.Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012 ;38(3):187-99.
• 24.Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999;289(2):1048-53.
• 25.Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. J Med Toxicol. 2018 ;14(4):306-322.
• 26.Gossop M, Griffiths P, Bradley B, Strang J (1989) Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. Br J Psychiatry 154:360–363
• 27.Strang J, Gossop M. Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts. Addict Behav. 1990;15(6):541-7.
• 28.Schuckit MA. Treatment of Opioid-Use Disorders. N Engl J Med. 2016 28;375(4):357-68.
• 29. Gloria Lai, Edwin N. Aroke, Sarah Jingying Zhang, Rediscovery of Methadone to Improve Outcomes in Pain Management, Journal of PeriAnesthesia Nursing Volume 37, Issue 4, 2022, Pages 425-434
• 30.Kharasch, E. D. and Stubbert, K. (2013), Role of Cytochrome P4502B6 in Methadone Metabolism and Clearance. J Clin Pharmacol, 53: 305-313.
• 31.Davis, M., Walsh, D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9, 73–83 (2001).
• 32. Verina Hanna, Helen Senderovich,Methadone in Pain Management: A Systematic Review,The Journal of Pain,Volume 22, Issue 3,2021,Pages 233-245
• 33.Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002 17;137(6):501-4.
• 34.Malboosbaf R, Hatami N, Maghsoomi Z. Methadone-induced hypoglycemia: A case report. J Diabetes Investig. 2023 ;14(1):145-146.
• 35.Gasimova U, Afzal KM, Acharya AB. Neurological Manifestations of Chronic Methadone Maintenance Therapy: A Case Report and Literature Review. Cureus. 2022 24;14(9):e29534.
• 36.Ghasemi S, Izadpanahi S, Yaghoubi MA, Brent J, Mehrpour O. Methadone associated long term hearing loss and nephrotoxicity; a case report and literature review. Subst Abuse Treat Prev Policy. 2019 6;14(1):48.
• 37.Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, Toll L. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol. 2015 ;172(2):668-80.
• 38.Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther. 2011 ;89(3):443-9.
• 39. D'Onofrio G, Chawarski MC, O'Connor PG, Pantalon MV, Busch SH, Owens PH, Hawk K, Bernstein SL, Fiellin DA. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. J Gen Intern Med. 2017 ;32(6):660-666.
• 40.D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015 28;313(16):1636-44.
• 41.Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017 21;2(2):CD002025.
• 42.Reed LJ, Glasper A, de Wet CJ, Bearn J, Gossop M. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients? J Clin Psychopharmacol. 2007 ;27(2):188-92.
• 43. Rudolph KE, Williams NT, Goodwin ATS, Shulman M, Fishman M, Díaz I, Luo S, Rotrosen J, Nunes EV. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug Alcohol Depend. 2022 1;239:109609.
• 44.Grande LA, Cundiff D, Greenwald MK, Murray M, Wright TE, Martin SA. Evidence on Buprenorphine Dose Limits: A Review. J Addict Med. 2023 01;17(5):509-516. 5.
• 45.Kumar R, Viswanath O, Saadabadi A. Buprenorphine. [Updated 2023 Nov 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 -.
• 46.Marquet, P. (2002). Pharmacology of High-Dose Buprenorphine. In: Kintz, P., Marquet, P. (eds) Buprenorphine Therapy of Opiate Addiction. Forensic Science and Medicine. Humana Press, Totowa,
• 47.Orman, J. S., Keating, G. M. Buprenorphine/Naloxone. Drugs 69, 577–607 (2009).
• 48.Olofsen E, Algera MH, Moss L, Dobbins RL, Groeneveld GJ, van Velzen M et al. Modeling buprenorphine reduction of fentanyl-induced respiratory depression. JCI Insight. 2022 9;7(9):e156973.
• 49.Sema Baykara, Kübra Alban, The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients, Psychiatry Research, Volume 272, 2019, Pages 450-453.
• 50.Urits I, Pham C, Swanson D, Berardino K, Bandi P, Amgalan A et al. The utilization of buprenorphine in chronic pain. Best Pract Res Clin Anaesthesiol. 2020 ;34(3):355-368.
• 51.Shulman, M., Wai, JM & Nunes, Opioid Kullanım Bozukluğu için EV Buprenorfin Tedavisi: Genel Bakış. CNS İlaçları 33, 567–580 (2019).
• 52.Singh D, Saadabadi A. Naltrexone. [Updated 2023 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024
• 53.Zhang P, Yang M, Chen C, Liu L, Wei X, Zeng S. Toll-Like Receptor 4 (TLR4)/Opioid Receptor Pathway Crosstalk and Impact on Opioid Analgesia, Immune Function, and Gastrointestinal Motility. Front Immunol. 2020 8;11:1455.
• 54.Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Med Sci (Basel). 2018 21;6(4):82.
• 55.Perez-Macia V, Martinez-Cortes M, Mesones J, Segura-Trepichio M, Garcia-Fernandez L. Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder. Patient Prefer Adherence. 2021 18;15:999-1015.
• 56.Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021 14;384(2):140-153.
• 57.Ornellas T, Chavez B. Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults. P T. 2011 ;36(5):255-62.
• 58. Gonzalez, JP, Brogden, RN Naltrekson. Drugs 35, 192–213 (1988).
• 59. Heck J, Burda K, Hillemacher T, Bleich S, Stichtenoth DO, Groh A. Naltrexone-induced drug eruption. Clin Case Rep. 2020 23;8(10):2049-2050.
• 60. SADOVE MS, BALAGOT RC, HATANO S, JOBGEN EA. Study of a narcotic antagonist--N-allyl-noroxymorphone. JAMA. 1963 23;183:666-8.
• 61. Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014 ;120(5):1262-74.
• 62. Saari TI, Strang J, Dale O. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clin Pharmacokinet. 2024 Apr;63(4):397-422. doi: 10.1007/s40262-024-01355-6. Epub 2024 Mar 14. PMID: 38485851; PMCID: PMC11052794.
• 63 Jarrar Y, Lee SJ. The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human Diseases. J Pers Med. 2021 14;11(6):554.
• 64.Weber JM, Tataris KL, Hoffman JD, Aks SE, Mycyk MB. Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose? Prehosp Emerg Care. 2012 ;16(2):289-92.
• 65. Williams, K., Lang, E. S., Panchal, A. R., Gasper, J. J., Taillac, P., Gouda, J., … Hedges, M. (2019). Evidence-Based Guidelines for EMS Administration of Naloxone. Prehospital Emergency Care, 23(6), 749–763.
• 66. Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016 ;81(3):428-36.
• 67.Maarten van Lemmen, Jeffrey Florian, Zhihua Li, Monique van Velzen, Eveline van Dorp, Marieke Niesters et al. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest. Anesthesiology 2023; 139:342–353
• 68.Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience, 9(4), 455–470.
• 69. Yasaei R, Saadabadi A. Clonidine. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459124/
• 70.Jamadarkhana S, Gopal S. Clonidine in adults as a sedative agent in the intensive care unit. J Anaesthesiol Clin Pharmacol. 2010 ;26(4):439-45.
• 71.Bhullar J, Patel A, Chitithoti J, Venter F, Win T, Joolhar F. Clonidine Overdose as an Unusual Cause of Heart Failure. J Investig Med High Impact Case Rep. 2022 ;10:23247096221106856